Therefore, the present study not only demonstrated the feedback reactivation of AKT pathway as a key mechanism for the resistance of CRC to SHP2 inhibition, but also provided the combination of SHP2 and each of the AKT and FAK pathway inhibition as potential strategies to enhance the efficacy of SHP2 inhibition. The gene discussed is AKT1; the disease is colorectal carcinoma.